- Oregon hospital threatens to refuse Medicare Advantage patients.
- Ten drugs, mostly used to treat rare diseases cost over $700,000 annually.
- How Big Pharma makes its money: AbbVie blanketed Humira, the best-selling drug in history, with 165 peripheral patents, to deter any possible competition.
- Medicine without doctors: The past several years have seen hundreds of laws proposing to expand non doctor medical professionals’ work, the AMA has spent millions of dollars fighting back. (Washington Post)
Category: Authors
The FDA Hinders the Progress of Regenerative Medicine
The U.S. Food and Drug Administration (FDA) sometimes gets lost in a bureaucratic maze of confusion and red tape that deprives patients of beneficial therapies. Innovative products sometimes fall within a gray area and become overly regulated. One of the FDA’s latest targets is regenerative medicine.
An article titled, An MBA in Regulatory Confusion, talks about Florida-based Regenative Labs. The firm manufactures products made from umbilical cords (donated by mothers after a C-section, according to the company website). English physician and anatomist Thomas Wharton first described his namesake umbilical cord jelly in 1656, although he had no way of knowing it is rich in stem cells and regenerative healing properties.
Saturday Links
- Reprint of a Uwe Reinhart classic: how Republican administrations gave us health care price controls and Keynesian economics fiscal policy.
- OxyContin and the Sacklers return to TV in a Netflix series fact checked by Slate.
- Blue Shield of California tears up the prescription drug playbook and partners with Mark Cuban Cost Plus Drug Company. (WSJ)
- Did you know the US government is stockpiling cheese ….. and raisins?
- What happens to the roughly 20 million people slated to lose Medicaid coverage? The vast majority have other insurance and apparently didn’t need to be on Medicaid in the first place. (WSJ)
- COVID experts calling for masks again — even at home!
Why is Medicare Money Paying for Teslas?
Much of the $280 billion in savings from its Medicare prescription drug provisions [the IRA bill] were siphoned off to fund green policies such as $7,500 electric-vehicle tax credits. Medicare will keep only about 15% of the savings for some relatively inexpensive new benefits, such as a $2,000 annual cap on pharmacy spending. That’s unfortunate considering the program’s costs are projected to spiral from about $1 trillion this year to $1.8 trillion in 2031.